{"disease":{"id":"embolism","name":"Embolism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":26},"drugs":{"marketed":[{"drug_id":"edoxaban","indication_name":"Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"edoxaban","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"dabigatran","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"chembl-chembl48361","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"dabigatran","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"chembl-chembl48361","indication_name":"Reduction of stroke and systemic embolism risk in non-valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"dabigatran","indication_name":"Prevention of systemic embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"xarelto","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bemiparin","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"BEMIPARIN","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Factor Xa and thrombin (via antithrombin III enhancement)","drug_class":"Low Molecular Weight Heparin","quality_score":0,"revenue":null,"mechanism":"Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade."},{"drug_id":"fondaparinux","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arixtra","generic_name":"FONDAPARINUX","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":67,"revenue":null,"mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting."},{"drug_id":"enoxaparin-sodium","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"enoxaparin-sodium","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"heparin","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Peripheral Arterial Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Peripheral arterial embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"rivaroxaban","indication_name":"Prevention of pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Prevention of systemic embolism caused by a clot in a blood vessel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Prevention of venous thromboembolism from re-occuring","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Prevention of venous thromboembolism in undergoing surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"dabigatran-etexilate","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"dabigatran-etexilate","indication_name":"Prevention of systemic embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"dabigatran-etexilate","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"fragmin","indication_name":"Extended treatment of symptomatic venous thromboembolism to reduce recurrence in adult patients with cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"fragmin","indication_name":"Treatment of symptomatic venous thromboembolism to reduce recurrence in pediatric patients from birth (gestational age at least 35 weeks)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"heparin-sodium","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Peripheral Arterial Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Peripheral arterial embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"acenocoumarol","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sintrom","generic_name":"ACENOCOUMAROL","company_name":"","drug_phase":"phase_3","molecular_target":"Vitamin K epoxide reductase complex subunit 1","drug_class":"acenocoumarol","quality_score":null,"revenue":null,"mechanism":"Acenocoumarol works by blocking the enzyme that helps produce clotting factors in the liver."},{"drug_id":"warfarin","indication_name":"Cerebral embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Thromboembolism due to Prosthetic Heart Valves","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"alteplase","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Activase","generic_name":"ALTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate","indication_name":"Reduction of stroke and systemic embolism risk in non-valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"clopidogrel","indication_name":"Cerebral embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"clopidogrel","indication_name":"Peripheral Arterial Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"arixtra","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arixtra","company_name":"LifeBridge Health","drug_phase":"marketed","molecular_target":"Antithrombin-III, Coagulation factor X","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lovenox","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lovenox","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"activase","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Activase","company_name":"Medical College of Wisconsin","drug_phase":"discontinued","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"enoxaparin","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dicoumarol","indication_name":"Cerebral embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dicuman","generic_name":"dicoumarol","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"NAD(P)H dehydrogenase [quinone] 1","drug_class":"dicoumarol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate-de","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"dabigatran-etexilate-de","indication_name":"Prevention of systemic embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"dabigatran-etexilate-de","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"xarelto","indication_name":"Prevention of pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Prevention of systemic embolism caused by a clot in a blood vessel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Prevention of venous thromboembolism from re-occuring","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Prevention of venous thromboembolism in undergoing surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Polycythemia vera and essential thrombocythemia (thromboembolism prevention)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":58,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT01653405","title":"Improving Anticoagulation Control in VISN 1","phase":"NA","overall_status":"COMPLETED","enrollment_count":1260576,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT03660007","title":"Incidence of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer","phase":"","overall_status":"COMPLETED","enrollment_count":902891,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04969653","title":"The Incidence of Venous Thromboembolism in Atopic Dermatitis","phase":"","overall_status":"COMPLETED","enrollment_count":754745,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT01947959","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","phase":"","overall_status":"COMPLETED","enrollment_count":665533,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04940377","title":"Effect of the Genotype on Postoperative DVT","phase":"","overall_status":"COMPLETED","enrollment_count":502505,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03271450","title":"The DARE Warfarin CER Study","phase":"","overall_status":"UNKNOWN","enrollment_count":416000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04569344","title":"COVID-19 and Venous Thromboembolism Risk","phase":"","overall_status":"COMPLETED","enrollment_count":398530,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT01947985","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","phase":"","overall_status":"COMPLETED","enrollment_count":208958,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06232551","title":"Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":152000,"lead_sponsor_name":"Scott C. Woller, MD","has_results":false},{"nct_id":"NCT02828904","title":"RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism","phase":"","overall_status":"COMPLETED","enrollment_count":124000,"lead_sponsor_name":"Center for Epidemiology and Health Research, Germany","has_results":false},{"nct_id":"NCT03799016","title":"An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":104215,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02468102","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04879407","title":"Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":98947,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03965741","title":"Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners","phase":"","overall_status":"COMPLETED","enrollment_count":97765,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03243708","title":"Title: Randomized Trial of an EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":90537,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03087474","title":"Treatment of Venous Thromboembolism in Real-Life Patients","phase":"","overall_status":"COMPLETED","enrollment_count":89383,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04736420","title":"Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":78605,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06020560","title":"Study of Low Molecular Weight Heparins","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":65000,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT05022563","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":55759,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01947998","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","phase":"","overall_status":"COMPLETED","enrollment_count":50299,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05264168","title":"Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":41875,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03292666","title":"Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study","phase":"","overall_status":"COMPLETED","enrollment_count":39603,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03521908","title":"A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot","phase":"","overall_status":"COMPLETED","enrollment_count":35756,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04615065","title":"Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT04141228","title":"A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US","phase":"","overall_status":"COMPLETED","enrollment_count":28000,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05058521","title":"Venous thromboEmbolism Risk Profiles in Chinese hoSpitalized patiEnts (VERSE Study)","phase":"","overall_status":"COMPLETED","enrollment_count":27490,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT04444804","title":"Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":22153,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06443905","title":"Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21600,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05347550","title":"Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":21472,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT06937372","title":"Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":21194,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05819125","title":"Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin","phase":"","overall_status":"TERMINATED","enrollment_count":21000,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02443610","title":"Haemorrhages and Thromboembolic Venous Disease of the Postpartum","phase":"","overall_status":"COMPLETED","enrollment_count":20241,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07328152","title":"CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - \"MC-MORPHEUS\".","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05568966","title":"Collection of Blood Samples for New Diagnostic Devices 2","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT07245927","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Supergene, LLC","has_results":false},{"nct_id":"NCT04736719","title":"Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19002,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04574895","title":"Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events","phase":"NA","overall_status":"COMPLETED","enrollment_count":17427,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT06806800","title":"Venous Thromboembolism During COVID-19 Pandemic: Evaluation of the Association With the Vaccine and COVID-19 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":16000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06353373","title":"Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies","phase":"","overall_status":"UNKNOWN","enrollment_count":15626,"lead_sponsor_name":"Navy General Hospital, Beijing","has_results":false},{"nct_id":"NCT05628207","title":"Evaluation of the SCALED (SCaling AcceptabLE cDs)","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT02943343","title":"The China Pulmonary Thromboembolism Registry Study","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05643573","title":"A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":14830,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05819112","title":"A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness","phase":"","overall_status":"TERMINATED","enrollment_count":14799,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05795062","title":"Treatment Patterns Among Patients With Venous Thromboembolism in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":13945,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04535128","title":"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications","phase":"","overall_status":"COMPLETED","enrollment_count":11000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04768036","title":"A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":10699,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT02155491","title":"Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events","phase":"","overall_status":"COMPLETED","enrollment_count":10679,"lead_sponsor_name":"Thrombosis Research Institute","has_results":false},{"nct_id":"NCT06581965","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10078,"lead_sponsor_name":"Leiden University Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}